keyword
MENU ▼
Read by QxMD icon Read
search

"glioblastoma" radiotherapy

keyword
https://www.readbyqxmd.com/read/28527010/glioblastoma-multiforme-gbm-in-the-elderly-initial-treatment-strategy-and-overall-survival
#1
Scott M Glaser, Michael J Dohopolski, Goundappa K Balasubramani, John C Flickinger, Sushil Beriwal
The EORTC trial which solidified the role of external beam radiotherapy (EBRT) plus temozolomide (TMZ) in the management of GBM excluded patients over age 70. Randomized studies of elderly patients showed that hypofractionated EBRT (HFRT) alone or TMZ alone was at least equivalent to conventionally fractionated EBRT (CFRT) alone. We sought to investigate the practice patterns and survival in elderly patients with GBM. We identified patients age 65-90 in the National Cancer Data Base (NCDB) with histologically confirmed GBM from 1998 to 2012 and known chemotherapy and radiotherapy status...
May 19, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28521700/glioblastoma-multiforme-diagnosis-and-treatment-recent-literature-review
#2
Ron Batash, Noam Asna, Pamela Schaffer, Nicole Francis, Moshe Schaffer
BACKGROUND: Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor, with an incidence of 3.19 cases per 100,000 person years and remarkably poor prognosis showing a 5-year survival rate of 4-5%, and only a 26-33% survival rate at 2 years in clinical trials. OBJECTIVE: In this paper, we review the different types of treatment modalities based on the relevant databases. Methods of diagnosis will be described briefly. METHOD: Systemic compilation of the relevant literature...
May 16, 2017: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/28514722/the-interventional-effect-of-new-drugs-combined-with-the-stupp-protocol-on-glioblastoma-a-network-meta-analysis
#3
Mei Li, Xiangqi Song, Jun Zhu, Aijun Fu, Jianmin Li, Tong Chen
OBJECTIVE: New therapeutic agents in combination with the standard Stupp protocol (a protocol about the temozolomide combined with radiotherapy treatment with glioblastoma was research by Stupp R in 2005) were assessed to evaluate whether they were superior to the Stupp protocol alone, to determine the optimum treatment regimen for patients with newly diagnosed glioblastoma. PATIENTS AND METHODS: We implemented a search strategy to identify studies in the following databases: PubMed, Cochrane Library, EMBASE, CNKI, CBM, Wanfang, and VIP, and assessed the quality of extracted data from the trials included...
May 11, 2017: Clinical Neurology and Neurosurgery
https://www.readbyqxmd.com/read/28512646/mri-in-glioma-immunotherapy-evidence-pitfalls-and-perspectives
#4
REVIEW
Domenico Aquino, Andrea Gioppo, Gaetano Finocchiaro, Maria Grazia Bruzzone, Valeria Cuccarini
Pseudophenomena, that is, imaging alterations due to therapy rather than tumor evolution, have an important impact on the management of glioma patients and the results of clinical trials. RANO (response assessment in neurooncology) criteria, including conventional MRI (cMRI), addressed the issues of pseudoprogression after radiotherapy and concomitant chemotherapy and pseudoresponse during antiangiogenic therapy of glioblastomas (GBM) and other gliomas. The development of cancer immunotherapy forced the identification of further relevant response criteria, summarized by the iRANO working group in 2015...
2017: Journal of Immunology Research
https://www.readbyqxmd.com/read/28505072/a-feasibility-study-of-personalized-prescription-schemes-for-glioblastoma-patients-using-a-proliferation-and-invasion-glioma-model
#5
Minsun Kim, Jakob Kotas, Jason Rockhill, Mark Phillips
Purpose: This study investigates the feasibility of personalizing radiotherapy prescription schemes (treatment margins and fractional doses) for glioblastoma (GBM) patients and their potential benefits using a proliferation and invasion (PI) glioma model on phantoms. Methods and Materials: We propose a strategy to personalize radiotherapy prescription schemes by simulating the proliferation and invasion of the tumor in 2D according to the PI glioma model. We demonstrate the strategy and its potential benefits by presenting virtual cases, where the standard and personalized prescriptions were applied to the tumor...
May 13, 2017: Cancers
https://www.readbyqxmd.com/read/28500559/nivolumab-for-patients-with-recurrent-glioblastoma-progressing-on-bevacizumab-a-retrospective-case-series
#6
Marc C Chamberlain, Bryan T Kim
A single institution retrospective evaluation of nivolumab following disease progression on bevacizumab in adults with recurrent glioblastoma (GBM) with an objective of determining progression free survival (PFS). There is no accepted therapy for recurrent GBM after failure of bevacizumab. 16 adults, ages 52-72 years (median 62), with recurrent GBM were treated. All patients had previously been treated with surgery, concurrent radiotherapy and temozolomide, and post-radiotherapy temozolomide. Bevacizumab (with or without lomustine) was administered to all patients at first recurrence...
May 12, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28499389/a-phase-ii-trial-of-autologous-dendritic-cell-vaccination-and-radiochemotherapy-following-fluorescence-guided-surgery-in-newly-diagnosed-glioblastoma-patients
#7
Susana Inogés, Sonia Tejada, Ascensión López-Díaz de Cerio, Jaime Gállego Pérez-Larraya, Jaime Espinós, Miguel Angel Idoate, Pablo Daniel Domínguez, Reyes García de Eulate, Javier Aristu, Maurizio Bendandi, Fernando Pastor, Marta Alonso, Enrique Andreu, Felipe Prósper Cardoso, Ricardo Díez Valle
BACKGROUND: Prognosis of patients with glioblastoma multiforme (GBM) remains dismal, with median overall survival (OS) of about 15 months. It is therefore crucial to search alternative strategies that improve these results obtained with conventional treatments. In this context, immunotherapy seems to be a promising therapeutic option. We hypothesized that the addition of tumor lysate-pulsed autologous dendritic cells (DCs) vaccination to maximal safe resection followed by radiotherapy and concomitant and adjuvant temozolomide could improve patients' survival...
May 12, 2017: Journal of Translational Medicine
https://www.readbyqxmd.com/read/28494176/comparative-analysis-of-the-effects-of-a-sphingosine-kinase-inhibitor-to-temozolomide-and-radiation-treatment-on-glioblastoma-cell-lines
#8
Liliana R Oancea-Castillo, Carmen Klein, Amir Abdollahi, Klaus-Josef Weber, Anne Régnier-Vigouroux, Ivana Dokic
Glioblastoma multiforme (GBM) exhibits high resistance to the standard treatment of temozolomide (TMZ) combined with radiotherapy, due to its remarkable cell heterogeneity. Accordingly, there is a need to target alternative molecules enhancing specific GBM autocrine or paracrine mechanisms and amplifying the effect of standard treatment. Sphingosine 1-phosphate (S1P) is such a lipid target molecule with an important role in cell invasion and proliferation. Sphingosine kinase inhibitors (SKI) prevent S1P formation and induce increased production of reactive oxygen species (ROS), which may potentiate radiation cytotoxicity...
May 11, 2017: Cancer Biology & Therapy
https://www.readbyqxmd.com/read/28490931/treatment-and-outcomes-for-glioblastoma-in-elderly-compared-with-non-elderly-patients-a-population-based-study
#9
E R Morgan, A Norman, K Laing, M D Seal
PURPOSE: Elderly patients make up a large percentage of the individuals newly diagnosed with glioblastoma (gbm), but they face particular challenges in tolerating standard therapy, and compared with younger patients, they experience significantly shorter survival. We set out to compare clinical characteristics, treatment patterns, and outcomes in a non-elderly group (<65 years) and an elderly group (≥65 years) of patients diagnosed with gbm. METHODS: This retrospective population-based study used a province-wide cancer registry to identify patients with a new diagnosis of gbm within a 6-year period (2006-2012)...
April 2017: Current Oncology
https://www.readbyqxmd.com/read/28483413/european-association-for-neuro-oncology-eano-guideline-on-the-diagnosis-and-treatment-of-adult-astrocytic-and-oligodendroglial-gliomas
#10
REVIEW
Michael Weller, Martin van den Bent, Jörg C Tonn, Roger Stupp, Matthias Preusser, Elizabeth Cohen-Jonathan-Moyal, Roger Henriksson, Emilie Le Rhun, Carmen Balana, Olivier Chinot, Martin Bendszus, Jaap C Reijneveld, Frederick Dhermain, Pim French, Christine Marosi, Colin Watts, Ingela Oberg, Geoffrey Pilkington, Brigitta G Baumert, Martin J B Taphoorn, Monika Hegi, Manfred Westphal, Guido Reifenberger, Riccardo Soffietti, Wolfgang Wick
The European Association for Neuro-Oncology guideline provides recommendations for the clinical care of adult patients with astrocytic and oligodendroglial gliomas, including glioblastomas. The guideline is based on the 2016 WHO classification of tumours of the central nervous system and on scientific developments since the 2014 guideline. The recommendations focus on pathological and radiological diagnostics, and the main treatment modalities of surgery, radiotherapy, and pharmacotherapy. In this guideline we have also integrated the results from contemporary clinical trials that have changed clinical practice...
May 5, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28479790/value-of-minimum-apparent-diffusion-coefficient-on-magnetic-resonance-imaging-as-a-biomarker-for-predicting-progression-of-disease-following-surgery-and-radiotherapy-in-glial-tumors-from-a-tertiary-care-center-in-northern-india
#11
Pramod Kumar Gupta, Rishi Awasthi, Shalini Singh, Sanjay Behari, K J Maria Das, Rakesh Kumar Gupta, Shaleen Kumar
PURPOSE: Studies have shown that cellularity of glial tumors are inversely correlated to minimum apparent diffusion coefficient (ADC) values derived on diffusion-weighted imaging (DWI). The purpose of this prospective exploratory study was to evaluate whether temporal change in "minimum ADC" values during follow-up predict progressive disease in glial tumors post radiotherapy and surgery. MATERIALS AND METHODS: Adult patients of glial tumors, subjected to surgery followed by Radiotherapy (RT), were included in the study...
April 2017: Journal of Neurosciences in Rural Practice
https://www.readbyqxmd.com/read/28472509/multicenter-phase-ii-study-of-temozolomide-and-myeloablative-chemotherapy-with-autologous-stem-cell-transplant-for-newly-diagnosed-anaplastic-oligodendroglioma
#12
Alissa A Thomas, Lauren E Abrey, Robert Terziev, Jeffrey Raizer, Nina L Martinez, Peter Forsyth, Nina Paleologos, Matthew Matasar, Craig S Sauter, Craig Moskowitz, Stephen D Nimer, Lisa M DeAngelis, Thomas Kaley, Sean Grimm, David N Louis, J Gregory Cairncross, Katherine S Panageas, Samuel Briggs, Geraldine Faivre, Nimish A Mohile, Jayesh Mehta, Philip Jonsson, Debyani Chakravarty, Jianjiong Gao, Nikolaus Schultz, Cameron W Brennan, Jason T Huse, Antonio Omuro
Background: Anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytomas (AOA) are chemotherapy-sensitive tumors with prolonged survival after radiochemotherapy. We report a prospective trial using induction temozolomide (TMZ) followed by myeloablative high-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT), as a potential strategy to defer radiotherapy. Methods: Patients with AO/AOA received 6 cycles of TMZ (200mg/m2 X5/28-day). Responding patients were eligible for HDC (thiotepa 250mg/m2/day X3 days then busulfan 3...
May 2, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28467795/survival-benefit-of-glioblastoma-patients-after-fda-approval-of-temozolomide-concomitant-with-radiation-and-bevacizumab-a-population-based-study
#13
Ping Zhu, Xianglin L Du, Guangrong Lu, Jay-Jiguang Zhu
Few population-based analyses have investigated survival change in glioblastoma multiforme (GBM) patients treated with concomitant radiotherapy-temozolomide (RT-TMZ) and adjuvant temozolomide (TMZ) and then bevacizumab (BEV) after Food and Drug Administration (FDA) approval, respectively. We aimed to explore the effects on survival with RT-TMZ, adjuvant TMZ and BEV in general GBM population based on the Surveillance, Epidemiology, and End Results (SEER) and Texas Cancer Registry (TCR) databases. A total of 28933 GBM patients from SEER (N = 24578) and TCR (N = 4355) between January 2000 and December 2013 were included...
April 12, 2017: Oncotarget
https://www.readbyqxmd.com/read/28464840/sparing-of-normal-tissues-with-volumetric-arc-radiation-therapy-for-glioblastoma-single-institution-clinical-experience
#14
Tina Marie Briere, Mary Frances McAleer, Lawrence B Levy, James N Yang
BACKGROUND: Patients with glioblastoma multiforme (GBM) require radiotherapy as part of definitive management. Our institution has adopted the use of volumetric arc therapy (VMAT) due to superior sparing of the adjacent organs at risk (OARs) compared to intensity modulated radiation therapy (IMRT). Here we report our clinical experience by analyzing target coverage and sparing of OARs for 90 clinical treatment plans. METHODS: VMAT and IMRT patient cohorts comprising 45 patients each were included in this study...
May 2, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/28454549/does-age-really-matter-radiotherapy-in-elderly-patients-with-glioblastoma-the-munich-experience
#15
Christoph Straube, Hagen Scherb, Jens Gempt, Stefanie Bette, Claus Zimmer, Friederike Schmidt-Graf, Jürgen Schlegel, Bernhard Meyer, Stephanie E Combs
BACKGROUND: Glioblastoma is usually diagnosed around the age of 60-70 years. Patients older than 65 years are frequently described as "elderly". Several trials with monotherapy have established treatment regimens that offer therapies with reduced side effects but reduced efficacy. We analysed the outcome of elderly glioblastoma patients treated at our facility. METHODS: We performed a retrospective analysis of 62 consecutive patients older than 65 years treated for a primary glioblastoma at our facility from 2009 to 2015...
April 28, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/28453747/natural-course-and-prognosis-of-anaplastic-gangliogliomas-a-multicenter-retrospective-study-of-43-cases-from-the-french-brain-tumor-database
#16
Louis-Marie Terrier, Luc Bauchet, Valérie Rigau, Aymeric Amelot, Sonia Zouaoui, Isabelle Filipiak, Agnès Caille, Fabien Almairac, Marie-Hélène Aubriot-Lorton, Anne-Marie Bergemer-Fouquet, Eric Bord, Philippe Cornu, Alain Czorny, Phong Dam Hieu, Bertrand Debono, Marie-Bernadette Delisle, Evelyne Emery, Walid Farah, Guillaume Gauchotte, Catherine Godfraind, Jacques Guyotat, Bernard Irthum, Kevin Janot, Pierre-Jean Le Reste, Dominique Liguoro, Hugues Loiseau, Guillaume Lot, Vincent Lubrano, Emmanuel Mandonnet, Philippe Menei, Philippe Metellus, Serge Milin, Bertrand Muckenstrum, Pierre-Hugues Roche, Audrey Rousseau, Emmanuelle Uro-Coste, Anne Vital, Jimmy Voirin, Michel Wager, Marc Zanello, Patrick François, Stéphane Velut, Pascale Varlet, Dominique Figarella-Branger, Johan Pallud, Ilyess Zemmoura
Background.: Anaplastic gangliogliomas (GGGs) are rare tumors whose natural history is poorly documented. We aimed to define their clinical and imaging features and to identify prognostic factors. Methods.: Consecutive cases of anaplastic GGGs in adults prospectively entered into the French Brain Tumor Database between March 2004 and April 2014 were screened. After diagnosis was confirmed by pathological review, clinical, imaging, therapeutic, and outcome data were collected retrospectively...
May 1, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28447277/assessment-of-pd-1-positive-cells-on-initial-and-secondary-resected-tumor-specimens-of-newly-diagnosed-glioblastoma-and-its-implications-on-patient-outcome
#17
Tsubasa Miyazaki, Eiichi Ishikawa, Masahide Matsuda, Hiroyoshi Akutsu, Satoru Osuka, Noriaki Sakamoto, Shingo Takano, Tetsuya Yamamoto, Koji Tsuboi, Akira Matsumura
Glioblastoma (GBM) is the most common type of malignant brain tumor and has a very poor prognosis. Most patients relapse within 12 months despite aggressive treatment and patient outcome after recurrent is extremely worse. This study was designed to clarify the change of the molecular expression, including programmed cell death 1 (PD-1) and PD-ligand 1 (PD-L1), on the initial and secondary resected tumor specimens and to address the influence of these expressions for patient outcome after second surgery of glioblastoma...
April 26, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28440040/hypofractionated-short-course-radiotherapy-in-elderly-patients-with-glioblastoma-multiforme-an-analysis-of-the-national-cancer-database
#18
Kimberley S Mak, Ankit Agarwal, Muhammad M Qureshi, Minh Tam Truong
For elderly patients with glioblastoma multiforme (GBM), randomized trials have shown similar survival with hypofractionated short-course radiotherapy (SCRT) compared to conventionally fractionated long-course radiotherapy (LCRT). We evaluated the adoption of SCRT along with associated factors and survival in a national patient registry. Using the National Cancer Data Base (NCDB), we identified patients aged ≥70 years with GBM, diagnosed between 1998 and 2011, who received SCRT (34-42 Gy in 2.5-3.4 Gy fractions), or LCRT (58-63 Gy in 1...
April 24, 2017: Cancer Medicine
https://www.readbyqxmd.com/read/28438859/automated-multichamber-time-lapse-videography-for-long-term-in-vivo-observation-of-migrating-cells
#19
Helmut Buhler, Raphael Adamietz, Theresa Abeln, David Diaz-Carballo, Pascaline Nguemgo-Kouam, Thomas Hero, Irenaus A Adamietz
AIM: To observe and document the migration of living cells by time-lapse videography, we constructed a low-budget system based on a common inverted microscope. MATERIALS AND METHODS: Long-term observation of six-well plates is enabled through maintenance of cell culture conditions (5% CO2 in air at 37°C). Points of interest can be revisited in definable intervals with <1 μm repositioning error. Digital photographs from each programmed time point are paired with environmental data and combined into a record...
May 2017: In Vivo
https://www.readbyqxmd.com/read/28438066/angiogenesis-inhibitors-in-tackling-recurrent-glioblastoma
#20
Thomas Hundsberger, David A Reardon, Patrick Y Wen
Despite aggressive multimodality treatment of glioblastoma, outcome remains poor and patients mostly die of local recurrences. Besides reoperation and occasionally reirradiation, systemic treatment of recurrent glioblastoma consists of alkylating chemotherapy (lomustine, temozolomide), bevacizumab and combinations thereof. Unfortunately, antiangiogenic agents failed to improve survival either as a monotherapy or in combination treatments. This review provides current insights into tumor-derived escape mechanisms and other areas of treatment failure of antiangiogenic agents in glioblastoma...
May 2, 2017: Expert Review of Anticancer Therapy
keyword
keyword
75725
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"